ATE482699T1 - Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson - Google Patents

Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson

Info

Publication number
ATE482699T1
ATE482699T1 AT03814205T AT03814205T ATE482699T1 AT E482699 T1 ATE482699 T1 AT E482699T1 AT 03814205 T AT03814205 T AT 03814205T AT 03814205 T AT03814205 T AT 03814205T AT E482699 T1 ATE482699 T1 AT E482699T1
Authority
AT
Austria
Prior art keywords
disease
methods
pharmaceutical compositions
treating parkinson
treating
Prior art date
Application number
AT03814205T
Other languages
English (en)
Inventor
Nancy Hathaway
Margery Mark
Original Assignee
Merck Frosst Company
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Company, Univ New Jersey Med filed Critical Merck Frosst Company
Application granted granted Critical
Publication of ATE482699T1 publication Critical patent/ATE482699T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT03814205T 2002-12-23 2003-12-19 Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson ATE482699T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43605102P 2002-12-23 2002-12-23
US44883303P 2003-02-20 2003-02-20
PCT/US2003/040561 WO2004058163A2 (en) 2002-12-23 2003-12-19 Pharmaceutical compositions and method of treating parkinson's disease

Publications (1)

Publication Number Publication Date
ATE482699T1 true ATE482699T1 (de) 2010-10-15

Family

ID=32685432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814205T ATE482699T1 (de) 2002-12-23 2003-12-19 Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson

Country Status (8)

Country Link
US (1) US20060154932A1 (de)
EP (1) EP1578412B1 (de)
JP (2) JP2006516549A (de)
AT (1) ATE482699T1 (de)
AU (1) AU2003301109B2 (de)
CA (1) CA2510289A1 (de)
DE (1) DE60334406D1 (de)
WO (1) WO2004058163A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
JP2010111581A (ja) * 2007-01-25 2010-05-20 Imuno:Kk ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2858500T3 (es) 2013-07-12 2021-09-30 Knopp Biosciences Llc Tratamiento de niveles elevados de eosinófilos y/o basófilos
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) * 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
JP2024510632A (ja) * 2021-03-23 2024-03-08 スピノジェニックス， インコーポレイテッド スパイン形成のためのある特定のファスシン結合化合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP1131102A2 (de) * 1998-11-12 2001-09-12 Merck & Co., Inc. Kombination von inverse agonisten des gaba-a alpha-5 rezeptor subtyps und cox-2 inhibitoren, nsaid, östrogen oder vitamin e
WO2001032170A1 (en) * 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
ES2267627T3 (es) * 2001-05-11 2007-03-16 Jurgen K. Dr. Beck Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal.
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)

Also Published As

Publication number Publication date
JP2010209093A (ja) 2010-09-24
JP2006516549A (ja) 2006-07-06
EP1578412A2 (de) 2005-09-28
CA2510289A1 (en) 2004-07-15
EP1578412B1 (de) 2010-09-29
EP1578412A4 (de) 2008-10-01
AU2003301109A8 (en) 2004-07-22
WO2004058163A2 (en) 2004-07-15
WO2004058163A3 (en) 2004-10-07
DE60334406D1 (de) 2010-11-11
AU2003301109B2 (en) 2009-06-25
US20060154932A1 (en) 2006-07-13
AU2003301109A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
ATE482699T1 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson
EA201892505A1 (ru) Амидозамещенные производные пиридинилтриазола и их применение
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
TW200621745A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200900900A1 (ru) Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20061033L (no) Sammensetninger og fremgangsmater for levering av biologiske aktive midler
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties